Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Li Y, Chen H, Li S, Li Y, Liu G, Bai J, et al
Food and Drug Administration approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity (body mass index of 30 kilograms per square meter (kg/ m2) or greater) or overweight (body mass index of 27 kg/m2 or greater) with at least one weight-related condition (such as high blood pressure, type 2 diabetes or high cholesterol) for use, in addition to a reduced calorie diet and increased physical activity
This is one of the reasons the clinical intake process exists and why the prescribing determination should never be treated as a formality
Real-world tolerance
Bringing any drug through Phase II and Phase III to regulatory approval costs hundreds of millions
If you have questions about BPC-157 or any of our other peptide and weight loss programs, contact us online or call to schedule your free consultation
